Logo image of NBIX

NEUROCRINE BIOSCIENCES INC (NBIX) Stock Fundamental Analysis

NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD

109.75  +0.07 (+0.06%)

After market: 124 +14.25 (+12.98%)

Fundamental Rating

7

Overall NBIX gets a fundamental rating of 7 out of 10. We evaluated NBIX against 563 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX is not overvalued while it is showing excellent growth. This is an interesting combination. This makes NBIX very considerable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year NBIX was profitable.
NBIX had a positive operating cash flow in the past year.
Each year in the past 5 years NBIX has been profitable.
In the past 5 years NBIX always reported a positive cash flow from operatings.
NBIX Yearly Net Income VS EBIT VS OCF VS FCFNBIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

NBIX has a better Return On Assets (9.18%) than 95.20% of its industry peers.
NBIX has a Return On Equity of 13.18%. This is amongst the best in the industry. NBIX outperforms 94.85% of its industry peers.
NBIX has a Return On Invested Capital of 13.20%. This is amongst the best in the industry. NBIX outperforms 96.45% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for NBIX is below the industry average of 14.24%.
The 3 year average ROIC (11.40%) for NBIX is below the current ROIC(13.20%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 9.18%
ROE 13.18%
ROIC 13.2%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
NBIX Yearly ROA, ROE, ROICNBIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

Looking at the Profit Margin, with a value of 14.49%, NBIX belongs to the top of the industry, outperforming 95.56% of the companies in the same industry.
NBIX's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 24.75%, NBIX belongs to the best of the industry, outperforming 96.63% of the companies in the same industry.
In the last couple of years the Operating Margin of NBIX has declined.
Looking at the Gross Margin, with a value of 98.56%, NBIX belongs to the top of the industry, outperforming 97.34% of the companies in the same industry.
In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
Industry RankSector Rank
OM 24.75%
PM (TTM) 14.49%
GM 98.56%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
NBIX Yearly Profit, Operating, Gross MarginsNBIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so NBIX is still creating some value.
Compared to 1 year ago, NBIX has more shares outstanding
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NBIX Yearly Shares OutstandingNBIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
NBIX Yearly Total Debt VS Total AssetsNBIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

NBIX has an Altman-Z score of 7.32. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
NBIX's Altman-Z score of 7.32 is amongst the best of the industry. NBIX outperforms 83.84% of its industry peers.
There is no outstanding debt for NBIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 7.32
ROIC/WACC1.31
WACC10.06%
NBIX Yearly LT Debt VS Equity VS FCFNBIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 3.40 indicates that NBIX has no problem at all paying its short term obligations.
With a Current ratio value of 3.40, NBIX is not doing good in the industry: 60.75% of the companies in the same industry are doing better.
A Quick Ratio of 3.28 indicates that NBIX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.28, NBIX perfoms like the industry average, outperforming 40.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.4
Quick Ratio 3.28
NBIX Yearly Current Assets VS Current LiabilitesNBIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

9

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 35.95% over the past year.
The Earnings Per Share has been growing by 58.39% on average over the past years. This is a very strong growth
Looking at the last year, NBIX shows a very strong growth in Revenue. The Revenue has grown by 24.81%.
Measured over the past years, NBIX shows a very strong growth in Revenue. The Revenue has been growing by 24.48% on average per year.
EPS 1Y (TTM)35.95%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-30.56%
Revenue 1Y (TTM)24.81%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%21.84%

3.2 Future

The Earnings Per Share is expected to grow by 38.15% on average over the next years. This is a very strong growth
Based on estimates for the next years, NBIX will show a quite strong growth in Revenue. The Revenue will grow by 12.63% on average per year.
EPS Next Y27.36%
EPS Next 2Y40.05%
EPS Next 3Y40.71%
EPS Next 5Y38.15%
Revenue Next Year13.3%
Revenue Next 2Y14.81%
Revenue Next 3Y14.65%
Revenue Next 5Y12.63%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NBIX Yearly Revenue VS EstimatesNBIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
NBIX Yearly EPS VS EstimatesNBIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15 20

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 33.36, NBIX can be considered very expensive at the moment.
94.14% of the companies in the same industry are more expensive than NBIX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of NBIX to the average of the S&P500 Index (28.10), we can say NBIX is valued inline with the index average.
A Price/Forward Earnings ratio of 26.19 indicates a quite expensive valuation of NBIX.
92.72% of the companies in the same industry are more expensive than NBIX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 20.74. NBIX is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 33.36
Fwd PE 26.19
NBIX Price Earnings VS Forward Price EarningsNBIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaper than 96.27% of the companies in the same industry.
95.56% of the companies in the same industry are more expensive than NBIX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 19.49
EV/EBITDA 13.26
NBIX Per share dataNBIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20 25

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of NBIX may justify a higher PE ratio.
A more expensive valuation may be justified as NBIX's earnings are expected to grow with 40.71% in the coming years.
PEG (NY)1.22
PEG (5Y)0.57
EPS Next 2Y40.05%
EPS Next 3Y40.71%

More info and screens

0

5. Dividend

5.1 Amount

NBIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUROCRINE BIOSCIENCES INC

NASDAQ:NBIX (5/5/2025, 6:02:21 PM)

After market: 124 +14.25 (+12.98%)

109.75

+0.07 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06 2025-02-06/amc
Earnings (Next)05-05 2025-05-05/amc
Inst Owners96.99%
Inst Owner Change-0.26%
Ins Owners1%
Ins Owner Change2.04%
Market Cap10.86B
Analysts83.13
Price Target157.97 (43.94%)
Short Float %4.51%
Short Ratio2.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-27.27%
Min EPS beat(2)-37.18%
Max EPS beat(2)-17.35%
EPS beat(4)0
Avg EPS beat(4)-38.78%
Min EPS beat(4)-59.17%
Max EPS beat(4)-17.35%
EPS beat(8)2
Avg EPS beat(8)-103.25%
EPS beat(12)2
Avg EPS beat(12)-88.07%
EPS beat(16)3
Avg EPS beat(16)-76.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.31%
Min Revenue beat(2)-2.16%
Max Revenue beat(2)1.54%
Revenue beat(4)2
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)5.99%
Revenue beat(8)4
Avg Revenue beat(8)0.67%
Revenue beat(12)7
Avg Revenue beat(12)1.15%
Revenue beat(16)8
Avg Revenue beat(16)0.23%
PT rev (1m)-5.09%
PT rev (3m)-7.53%
EPS NQ rev (1m)-38.11%
EPS NQ rev (3m)-60.53%
EPS NY rev (1m)-6.04%
EPS NY rev (3m)-34.41%
Revenue NQ rev (1m)-6.12%
Revenue NQ rev (3m)-10.07%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-3.99%
Valuation
Industry RankSector Rank
PE 33.36
Fwd PE 26.19
P/S 4.61
P/FCF 19.49
P/OCF 18.24
P/B 4.19
P/tB 4.25
EV/EBITDA 13.26
EPS(TTM)3.29
EY3%
EPS(NY)4.19
Fwd EY3.82%
FCF(TTM)5.63
FCFY5.13%
OCF(TTM)6.02
OCFY5.48%
SpS23.81
BVpS26.17
TBVpS25.81
PEG (NY)1.22
PEG (5Y)0.57
Profitability
Industry RankSector Rank
ROA 9.18%
ROE 13.18%
ROCE 18.16%
ROIC 13.2%
ROICexc 32.81%
ROICexgc 33.77%
OM 24.75%
PM (TTM) 14.49%
GM 98.56%
FCFM 23.66%
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexcg growth 3Y35.59%
ROICexcg growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score9
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 140.96%
Cap/Sales 1.62%
Interest Coverage 364.38
Cash Conversion 97.59%
Profit Quality 163.26%
Current Ratio 3.4
Quick Ratio 3.28
Altman-Z 7.32
F-Score9
WACC10.06%
ROIC/WACC1.31
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)35.95%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%-30.56%
EPS Next Y27.36%
EPS Next 2Y40.05%
EPS Next 3Y40.71%
EPS Next 5Y38.15%
Revenue 1Y (TTM)24.81%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%21.84%
Revenue Next Year13.3%
Revenue Next 2Y14.81%
Revenue Next 3Y14.65%
Revenue Next 5Y12.63%
EBIT growth 1Y47.67%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year-5.15%
EBIT Next 3Y24.31%
EBIT Next 5Y16.45%
FCF growth 1Y54.09%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y52.71%
OCF growth 3Y32.41%
OCF growth 5Y31.38%